CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 80 enrolled
Drug / intervention
sitagliptin phosphate +2 moredrug
Likely dose
sitagliptin phosphate 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00758069
NCT00758069Phase 2Completed
CompareCT.gov

Phase II Study on Sitagliptin -Assessment of Glucose-lowering Effects

Merck Sharp & Dohme LLC·interventional·Posted Sep 23, 2008·Updated May 5, 2017

In Brief

A Phase 2 clinical trial evaluating sitagliptin phosphate, Comparator: Placebo, and 1 other intervention for Diabetes Mellitus, Non-Insulin-Dependent. Completed, enrolled 80 participants.

Detailed Summary

A clinical study determines the safety and efficacy of sitagliptin (MK0431) in patients with Type 2 diabetes mellitus who have inadequate glycemic control on diet/exercise therapy

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Non-Insulin-Dependent
Countries--
Collaborators--

Timeline

Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 23, 2008
Enrollment StartJul 3, 2005
Primary CompletionFeb 13, 2006
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 17.8 years ago

Interventions

sitagliptin phosphatedrug

100 mg once daily (QD), taken orally for 4 weeks

Comparator: Placebodrug

Placebo tablet, QD, taken orally for 4 weeks

Comparator: Sitagliptindrug

50 mg twice daily (BID), taken orally for 4 weeks